Update on the immunobiology of Sjögren's syndrome

Current Opinion in Rheumatology

Volumn 27, Issue 5, 2015, Pages 468-475

  Ambrosi, Aurélie ^a   Wahren Herlenius, Marie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

B cell; Genetic association; IFN; Sj gren's syndrome

Indexed keywords

B CELL ACTIVATING FACTOR; GAMMA INTERFERON; INTERLEUKIN 17; INTERFERON;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; GENETIC ASSOCIATION; GERMINAL CENTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOBIOLOGY; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; TARGET ORGAN; TH1 CELL; TH17 CELL; IMMUNOLOGY; T LYMPHOCYTE; VIROLOGY;

ADAPTIVE IMMUNITY; B-LYMPHOCYTES; HUMANS; INTERFERON TYPE I; KILLER CELLS, NATURAL; SALIVARY GLANDS; SJOGREN'S SYNDROME; T-LYMPHOCYTES;

EID: 84942591193     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000195     Document Type: Review

References (50)

1. Kvarnstrom M, Ottosson V, Nordmark B, Wahren-Herlenius M. Incident cases of primary Sjogren's syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumat ol 2015; 44:135-142. This is the first prospective, population-based study looking at the incidence rate of pSS. The authors reported an incidence rate of 3.1 cases per 100 000 personyears. Interestingly, the prevalence of autoantibodies in this cohort of incident cases is lower than previously reported, and severe extraglandular manifestations are less frequent than in prevalent pSS.
2. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN p athways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci U S A 2006; 103:2770-2775.
3. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013; 72:728-735. This study shows that an I FN signature is present in up to 60% of pSS patients and that it is associated with higher disease activity and the presence of autoantibodies, highlighting the importance of the type I IFN system in pSS pathogenesis.
4. Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52:1185-1195.
5. Ambrosi A, Espi nosa A, Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol 2012; 42:2274-2284.
6. Espinosa A, Dardalhon V, Brauner S, et al. Loss of the lu pus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009; 206:1661-1671.
7. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:307-336.
8. Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in bo th innate and adaptive immune responses are associated with Sjogren's syndrome. Nat Genet 2013; 45:1284-1292. One of the first two GWAS performed in pSS. Importantly, this study finds associations between pSS and polymorphisms in gen es involved in IFN and B cell responses, strengthening the idea that genetic susceptibility related to these two immune-related pathways plays an important role in pSS pathogenesis.
9. Kallionpaa H, Elo LL, Laajala E, et al. Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility. Diabetes 2014; 63:2402-2414.
10. Lucchesi D, Pitzalis C, Bombardieri M. EBV and other viruses as triggers of tertiary lymphoid structures in primary Sjogren's syndrome. Expert Rev Clin Immunol 2014; 10:445-455. Comprehensive review looking at the current evidence supporting a role for viruses in pSS initiation/persistence. In p a rticular, the authors reflected on the possible link between viral infections, the formation of ectopic lymphoid structures, and the development/maintenance of autoimmune responses in target organs.
11. Bombardieri M, Barone F, Lucchesi D, et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. J Immunol 2012; 189:3767-3776. Important study supporting a ro le for viral infections in pSS pathogenesis. The authors demonstrated that administration of adenovirus to the salivary glands of mice led to features of pSS, including formation of ectopic lymphoid structures in the glands, production of autoantibodies, and reduced salivary flow.
12. Jin JO, Shinohara Y, Yu Q. Innate immune signaling induces interleukin-7 production from sali vary gland cells and accelerates the development of primary Sjogren's syndrome in a mouse model. PLoS One 2013; 8:e77605. Study linking an initial virally induced innate immune response to the development of adaptive immune responses and disease acce leration in a mouse model of pSS.
13. Croia C, Astorri E, Murray-Brown W, et al. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjogren 's syndrome. Arthritis Rheumatol 2014; 66:2545-2557. This study shows that there may be a particular connection between persistent viral infections (such as EBV) and the presence of ectopic lymphoid structures and autoantibody produc tion in pSS patients.
14. Salomonsson S,Jonsson MV,Skarstein K,et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome Ar thritis Rheum 2003 48 3187-3201.
15. Maehara T, Moriyama M, Hayashida JN, et al. Selective localization of T helper subsets in labial salivary glands from primary Sjogren's syndrome patients. Cl in Exp Immunol 2012; 169:89-99.
16. Szabo K, Papp G, Dezso B, Zeher M. The histopathology of labial salivary glands in primary Sjogren's syndrome: focusing on follicular helper T cells in the inflamm atory infiltrates. Mediators Inflamm 2014; 2014:631787.
17. Jin L, Yu D, Li X, et al. CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary S jogren's syndrome. Int J Clin Exp Pathol 2014; 7:1988-1996.
18. Bolstad AI, Le Hellard S, Kristjansdottir G, et al. Association between genetic variants in the tumour necrosis factor/lymphotoxin alpha/lymphotoxin beta locus and primary Sjogren's syndrome in Scandinavian samples. Ann Rheu m Dis 2012; 71:981-988.
19. Reksten TR, Johnsen SJ, Jonsson MV, et al. Genetic associations to germinal centre formation in primary Sjogren's syndrome. Ann Rheum Dis 2014; 73:1253-1258. Thi s study identifies genetic variations that are selectively associated with the presence of ectopic lymphoid structures in the salivary glands of pSS patients, supporting the idea that individuals with such histopathologic characteristics may represent a d istinct disease phenotype.
20. Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011; 70:1363-1368. Important study showing that the presence of germinal center-like structures in salivary glands is a useful and highly predictive marker for lymphoma development in pSS patients.
21. Amft N, Curnow SJ, Scheel-Toellner D, et al. Ectopic expression of the B cellattracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like s tructures in Sjogren's syndrome. Arthritis Rheum 2001; 44:2633-2641.
22. Barone F, Bombardieri M, Rosado MM, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogre n's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008; 180:5130-5140.
23. Ciccia F, Guggino G, Rizzo A, et al. Potential involveme nt of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2012; 71:295-301.
24. Gong YZ, Nititham J, Taylor K, et al. Differentiati on of follicular helper T cells by salivary gland epithelial cells in primary Sjogren's syndrome. J Autoimmun 2014; 51:57-66.
25. Ittah M, Miceli-Richard C,Gottenberg JE, et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR-And type-I IFN-dependent and-independent pathways. Eur J Immunol 2008; 38:1058-1064.
26. Nakamura H, Takahashi Y, Yamamoto-Fukuda T, et al. Direct infection of primary salivary gland epithelial cells by humanT lymphotropic virus type I in patients with Sjogren's syndrome. Arthritis Rheumatol 2015; 67:1096-1106.
27. Salomonsson S, Larsson P, Tengner P, et al. Expression of the B cellattracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogren's syndrome. Scand J Immunol 2002; 55:336-342.
28. Roescher N, Vosters JL, Alsaleh G, et al. Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjogren's syndrome as a proof of concept. Mol Ther 2014; 22:821-827.
29. Aqrawi LA, Kvarnstrom M, Brokstad KA, et al. Ductal epithelial expression of Ro52 correlates with inflammation in salivary gl ands of patients with primary Sjogren's syndrome. Clin Exp Immunol 2014; 177:244-252.
30. Mariette X,Seror R,Quartuccio L,et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: resu lts of the BELISS open-label phase II study Ann Rheum Dis 2015 74 526-531. First phase II clinical trial investigating the efficacy and safety of belimumab, a BAFF-blocking antibody, in the treatment of pSS. The primary end-point w as achieved in 60% of patients, indicating that targeting BAFF may be a promising therapeutic strategy in pSS that warrants larger randomized controlled trials.
31. Pontarini E, Fabris M, Quartuccio L, et al. Treatmen t with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2015.
32. Quartuccio L, Salvin S, Fabris M, e t al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013; 52:276-281.
33. Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the p rospective ASSESS cohort. PLoS One 2013; 8:e59868.
34. Nordmark G, Kristjansdottir G, Theander E, et al. Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjogren's syndrome. Genes Immun 2011; 12:100-109.
35. Li Y, Zhang K, Chen H, et al. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjogren's syndrome at 7q11.23. Nat Genet 2013; 45:1361-1365. One of the first two GWAS performed in pSS. This study confirms in a Han Chinese population genetic associations previously reported in European populations in the HLA locus as well as in loci including STAT4 and TNFAIP3. It al so identifies a new susceptibility locus, GTF2IRD1-GTF2I.
36. Nocturne G, Boudaoud S, Miceli-Richard C, et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 2013; 122:4068-4076. This study shows that mutations in TNFAIP3, which encodes a key regulator of NF-kB activation,areassociatedwithprogressiontowardlymphomadevelopment inasubstantial proportion of pSS patients, suggesting a pos sible mechanismfor progression from autoimmunity to lymphomagenesis in the context of chronic B cell activation in pSS.
37. Maier-Moore JS, KoelschKA, Smith K, et al. Antibody-secreting cell specificity in labial salivary glands reflects the clinical presentation and serology in patients with Sjogren's syndrome. Arthritis Rheumatol 2014; 66:3445-3456.
38. Hamza N, Hershberg U, Kallenberg CG, et al. Ig gene analy sis reveals altered selective pressures on Ig-producing cells in parotid glands of primary Sjogren's syndrome patients. J Immunol 2015; 194:514-521.
39. Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multicenter, follow-up study. Arthritis Res Ther 2013; 15:R172.
40. Gottenberg JE,Cinquetti G,Larroche C,et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013 72 1026-1031.
41. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med 2014; 160:233-242. Double-blind rand omized controlled trial of B cell depletion therapy (Rituximab) in pSS.Nosignificant improvement insymptomsor disease activitywas found6months after treatment, highlighting the need to target additional pathways related to pSS pathogenesis in order to ach ieve satisfactory treatment of pSS.
42. Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 2014; 73:1393-1396. Small proof-of-concept clinical trial showing that blocking T cell costimulation (Abatacept) may be useful in the treatment of pSS. Disease activity as well as RF and IgG levels decreased during and a fter treatment, while fatigue and quality of life reported by patients improved.
43. Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity define the origin of interferon signature s in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 2012; 109:17609-17614.
44. Alunno A, Bistoni O, Bartoloni E, et al. IL-17-producing CD4-CD8-T cells are expanded in the periph eral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. Ann Rheum Dis 2013; 72:286-292.
45. Alunno A, Carubbi F, Bistoni O, et al. CD4(-)CD8(-) T-cells in primary Sjogren's syndrome: association with the extent of glandular involvement. J Autoimmun 2014; 51:38-43.
46. Fei Y, Zhang W, Lin D, et al. Clinical parameter and T h17 related to lymphocytes infiltrating degree of labial salivary gland in primary Sjogren's syndrome. Clin Rheumatol 2014; 33:523-529.
47. Katsifis GE, Rekka S, Moutsopoulos NM, et al. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009; 175:1167-1177.
48. Lin X, Rui K, Deng J, et al. Th17 cells play a critical role in the development of experimental Sjogren's syndrome. Ann Rheum Dis 2015; 74:1302-1310.
49. Iizuka M, Tsuboi H, Matsuo N, et al. A crucial role of RORgammat in the development of spontaneous Sialadenitis-like Sjogren's syndrome. J Immunol 2015; 194:56-67.
50. Rusakiewicz S,Nocturne G,Lazure T,et al NCR3/NKp30 contributes to pathogenesis in primarySjogren'ssyndrome.Sci TranslMe d2013 5 196-196. This study identifies an association between a polymorphism in the NCR3 locus and susceptibility to pSS, and shows that elevated levels of the NCR3-encoded NK cell-Activating receptor in pSS patients correlate with enhanced se cretion of IFNg by NK cells. These new findings support a role for NK cells in pSS that warrants further investigation.